This was a prospective observational study evaluating the prognostic significance of ctDNA, such as exon 19 deletion, L858R, T790M, and C797S EGFR mutations, in patients with previously treated NSCLC harboring T790M EGFR mutation who received osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.